Strides Pharma Science Ltd has reported a robust financial performance for the first quarter of FY26, with consolidated revenue reaching INR 1,119.7 crore — a 6.2 percent increase from INR 1,053.9 crore recorded in the same quarter of the previous fiscal year.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at INR 218.1 crore, reflecting a 14.8 percent year-on-year growth. The company’s EBITDA margin improved significantly to 19.5 percent, up by 150 basis points compared to the same quarter last year. Operational profit after tax (PAT) surged by 80.6 percent to INR 114 crore, while the reported PAT stood at INR 105.6 crore. Operational earnings per share (EPS) for the quarter was INR 12.4.

Revenue from the US business stood at approximately INR 592 crore (equivalent to 71 million US dollars), registering a 7 percent year-on-year growth, reaffirming the region’s strategic importance in the company’s revenue mix.

Commenting on the performance, Badree Komandur, Managing Director and Group CEO of Strides Pharma, said, “We are pleased to begin the financial year on a strong note, marked by consistent growth and improved profitability. Our disciplined execution and cost control initiatives contributed to strong operating leverage, resulting in our highest-ever quarterly PAT. Return on capital employed (ROCE) stood at 15.1 percent for the quarter.”

Looking ahead, Strides Pharma plans to scale up investments in research and development to ensure long-term sustainable growth across its global markets.